Tenax Therapeutics - Pangali EV/EBITDA TENX

Tenax Therapeutics (TENX) strategy relies on patent protection for pulmonary hypertension therapies, which will ensure premium pricing in the future. The company delegates the final stages of clinical trials to external CRO partners through strict contracts. The business specializes in heart failure treatment for cardiac centers, developing oral levosimendan. This EV/EBITDA price action chart captured a value of 0.00, characterizing the asset's current valuation.

When constructing a long-term portfolio, screening capital-intensive assets requires analyzing the ratio of total enterprise value to operating profit before depreciation and interest. This metric determines the investment payback period, which is critical for Tenax Therapeutics (TENX), as financial success depends on clinical trial outcomes that determine the future profitability of the company's EV/EBITDA multiple.